Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page displays a new revision label, updating from v3.5.4 to v3.5.5 to reflect a minor update to the study record.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision tag updated to v3.5.4, replacing the previous v3.5.3, indicating an updated set of study documents on the page. This reflects a documentation revision rather than a change to the study data or eligibility criteria.SummaryDifference0.0%

- Check38 days agoChange DetectedTaoyuan, Taiwan has been added as a site and Taoyuan District, Taiwan has been removed from the study locations. This updates the geographic footprint of the trial sites for INSIGHT.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page’s footer “Revision” has been updated from v3.5.2 to v3.5.3, indicating a platform/version change rather than a change to the trial’s published information.SummaryDifference0.0%

- Check52 days agoChange DetectedSystem revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check81 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.